Evidence map›Paper›PMID 30706993›Full record

ArticleCurrent protocols in protein science2019

Tandem Affinity Purification and Mass Spectrometry (TAP-MS) for the Analysis of Protein Complexes.

Guillaume Adelmant, Brijesh K Garg, Maria Tavares, Joseph D Card, Jarrod A Marto

Open access · greenAbstract read
In one paragraph

Article in Current protocols in protein science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. eLife · 2020
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Guillaume AdelmantDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brijesh K GargDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Maria TavaresDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Joseph D CardDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jarrod A MartoDepartment of Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
Dana-Farber Cancer Institute · US

Funding

Genomic Analysis of Network Perturbations in Human DiseaseP50HG004233 · NHGRI · DANA-FARBER CANCER INST · PI VIDAL, MARC · 2007 to 2017
$31.6M
Transcriptional control of inhibitory synapse formationP01NS047572 · NINDS · DANA-FARBER CANCER INSTITUTE · PI STILES, CHARLES D · 2004 to 2013
$13.5M
PROJECT 4: Interrogating PP2A Signaling in Human CancersP01CA203655 · NCI · DANA-FARBER CANCER INST · PI DECAPRIO, JAMES A. · 2017 to 2021
$8.0M
Spatial Considerations in Neuronal Survival SignalsR01NS050674 · NINDS · DANA-FARBER CANCER INSTITUTE · PI SEGAL, ROSALIND A. · 2005 to 2021
$5.9M
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell LymphomaR01CA219850 · NCI · DANA-FARBER CANCER INST · PI DANIAL, NIKA N, MARTO, JARROD A. · 2018 to 2022
$2.8M
MYB family alterations in pediatric gliomasR01CA215489 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, LIGON, KEITH LLOYD · 2017 to 2021
$2.8M
Phosphoproteomic signatures for early detection and stratification of AMLR21CA188881 · NCI · DANA-FARBER CANCER INST · PI KENTSIS, ALEX, MARTO, JARROD A. · 2015 to 2016
$420k
Development of deep proteomic sequencing platforms for molecular markers in DLBCLR21CA178860 · NCI · DANA-FARBER CANCER INST · PI DANIAL, NIKA N, MARTO, JARROD A. · 2013 to 2014
$412k
NCI NIH HHS P01 CA203655NCI NIH HHS R01 CA215489NCI NIH HHS R01 CA219850NCI NIH HHS R21 CA178860NCI NIH HHS R21 CA188881NHGRI NIH HHS P50 HG004233NINDS NIH HHS P01 NS047572NINDS NIH HHS R01 NS050674
6 · The paper itself

Abstract

Affinity purification followed by mass spectrometry has become the technique of choice to identify binding partners in biochemical complexes isolated from a physiologic cellular context. In this report we detail our protocol for tandem affinity purification (TAP) primarily based on the use of the FLAG and HA peptide epitopes, with a particular emphasis on factors affecting yield and specificity, as well as steps to implement an automated version of the TAP procedure. © 2019 by John Wiley & Sons, Inc.

Indexed as

HEK293 CellsHeLa CellsHumansOligopeptidesProteomicsRetroviridaeTandem Affinity PurificationTandem Mass SpectrometryFLAG peptideOligopeptidesaffinity purificationepitope tagsmass spectrometryprotein complexprotein-protein interactionTAP

Identifiers

PMID30706993
PMCPMC6579647
OpenAlexW2914625462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.